- Home
- WELL vs AMGN Comparison
WELL vs AMGN Comparison
Compare WELL & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WELL
- AMGN
- Stock Information
- Founded
- WELL 1970
- AMGN 1980
- Country
- WELL United States
- AMGN United States
- Employees
- WELL N/A
- AMGN N/A
- Industry
- WELL Real Estate Investment Trusts
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WELL Real Estate
- AMGN Health Care
- Exchange
- WELL Nasdaq
- AMGN Nasdaq
- Market Cap
- WELL 131.1B
- AMGN 150.8B
- IPO Year
- WELL N/A
- AMGN N/A
- Fundamental
- Price
- WELL $206.89
- AMGN $343.30
- Analyst Decision
- WELL Strong Buy
- AMGN Hold
- Analyst Count
- WELL 10
- AMGN 14
- Target Price
- WELL $201.00
- AMGN $313.31
- AVG Volume (30 Days)
- WELL 3.5M
- AMGN 3.0M
- Earning Date
- WELL 10-27-2025
- AMGN 11-04-2025
- Dividend Yield
- WELL 1.44%
- AMGN 2.76%
- EPS Growth
- WELL N/A
- AMGN 65.12
- EPS
- WELL 1.46
- AMGN 12.93
- Revenue
- WELL $9,907,853,000.00
- AMGN $35,971,000,000.00
- Revenue This Year
- WELL $29.51
- AMGN $8.82
- Revenue Next Year
- WELL $14.35
- AMGN $1.84
- P/E Ratio
- WELL $141.37
- AMGN $26.64
- Revenue Growth
- WELL 32.28
- AMGN 10.56
- 52 Week Low
- WELL $123.11
- AMGN $253.30
- 52 Week High
- WELL $206.94
- AMGN $345.84
- Technical
- Relative Strength Index (RSI)
- WELL 82.77
- AMGN 69.85
- Support Level
- WELL $194.64
- AMGN $331.71
- Resistance Level
- WELL $201.42
- AMGN $345.49
- Average True Range (ATR)
- WELL 3.58
- AMGN 7.96
- MACD
- WELL 0.89
- AMGN 0.13
- Stochastic Oscillator
- WELL 98.32
- AMGN 94.13
About WELL Welltower Inc.
Welltower owns a diversified healthcare portfolio of 2,391 in-place properties spread across the senior housing, medical office, and skilled nursing/postacute care sectors. The portfolio includes over 100 properties in Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to that of the United States.
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.